# PRISMA 2020 Checklist

| Section and Topic | Item # | Checklist item | Indicate if the item is reported |
|---|---|---|---|
| **TITLE** | | | |
| Title | 1 | Identify the report as a systematic review. | yes |
| **ABSTRACT** | | | |
| Abstract | 2 | See the PRISMA 2020 for Abstracts checklist. | yes |
| **INTRODUCTION** | | | |
| Rationale | 3 | Describe the rationale for the review in the context of existing knowledge. | yes |
| Objectives | 4 | Provide an explicit statement of the objective(s) or question(s) the review addresses. | yes |
| **METHODS** | | | |
| Eligibility criteria | 5 | Specify the inclusion and exclusion criteria for the review and how studies were grouped for the syntheses. | yes |
| Information sources | 6 | Specify all databases, registers, websites, organisations, reference lists and other sources searched or consulted to identify studies. Specify the date when each source was last searched or consulted. | yes |
| Search strategy | 7 | Present the full search strategies for all databases, registers and websites, including any filters and limits used. | yes |
| Selection process | 8 | Specify the methods used to decide whether a study met the inclusion criteria of the review, including how many reviewers screened each record and each report retrieved, whether they worked independently, and if applicable, details of automation tools used in the process. | yes |
| Data collection process | 9 | Specify the methods used to collect data from reports, including how many reviewers collected data from each report, whether they worked independently, any processes for obtaining or confirming data from study investigators, and if applicable, details of automation tools used in the process. | yes |
| Data items | 10a | List and define all outcomes for which data were sought. Specify whether all results that were compatible with each outcome domain in each study were sought (e.g. for all measures, time points, analyses), and if not, the methods used to decide which results to collect. | yes |
| | 10b | List and define all other variables for which data were sought (e.g. participant and intervention characteristics, funding sources). Describe any assumptions made about any missing or unclear information. | yes |
| Study risk of bias assessment | 11 | Specify the methods used to assess risk of bias in the included studies, including details of the tool(s) used, how many reviewers assessed each study and whether they worked independently, and if applicable, details of automation tools used in the process. | yes |
| Effect measures | 12 | Specify for each outcome the effect measure(s) (e.g. risk ratio, mean difference) used in the synthesis or presentation of results. | yes |
| Synthesis methods | 13a | Describe the processes used to decide which studies were eligible for each synthesis (e.g. tabulating the study intervention characteristics and comparing against the planned groups for each synthesis (item #5)). | yes |
| | 13b | Describe any methods required to prepare the data for presentation or synthesis, such as handling of missing summary statistics, or data conversions. | yes |
| | 13c | Describe any methods used to tabulate or visually display results of individual studies and syntheses. | yes |
| | 13d | Describe any methods used to synthesize results and provide a rationale for the choice(s). If meta-analysis was performed, describe the model(s), method(s) to identify the presence and extent of statistical heterogeneity, and software package(s) used. | yes |
| | 13e | Describe any methods used to explore possible causes of heterogeneity among study results (e.g. subgroup analysis, meta-regression). | yes |
| | 13f | Describe any sensitivity analyses conducted to assess robustness of the synthesized results. | yes |
| Reporting bias assessment | 14 | Describe any methods used to assess risk of bias due to missing results in a synthesis (arising from reporting biases). | yes |
| Certainty assessment | 15 | Describe any methods used to assess certainty (or confidence) in the body of evidence for an outcome. | yes |

# PRISMA 2020 Checklist

| Section and Topic | Item # | Checklist item | Indicate if the item is reported |
|---|---|---|---|
| **RESULTS** | | | |
| Study selection | 16a | Describe the results of the search and selection process, from the number of records identified in the search to the number of studies included in the review, ideally using a flow diagram. | yes |
| | 16b | Cite studies that might appear to meet the inclusion criteria, but which were excluded, and explain why they were excluded. | yes |
| Study characteristics | 17 | Cite each included study and present its characteristics. | yes |
| Risk of bias in studies | 18 | Present assessments of risk of bias for each included study. | yes |
| Results of individual studies | 19 | For all outcomes, present, for each study: (a) summary statistics for each group (where appropriate) and (b) an effect estimate and its precision (e.g. confidence/credible interval), ideally using structured tables or plots. | yes |
| Results of syntheses | 20a | For each synthesis, briefly summarise the characteristics and risk of bias among contributing studies. | yes |
| | 20b | Present results of all statistical syntheses conducted. If meta-analysis was done, present for each the summary estimate and its precision (e.g. confidence/credible interval) and measures of statistical heterogeneity. If comparing groups, describe the direction of the effect. | yes |
| | 20c | Present results of all investigations of possible causes of heterogeneity among study results. | yes |
| | 20d | Present results of all sensitivity analyses conducted to assess the robustness of the synthesized results. | yes |
| Reporting biases | 21 | Present assessments of risk of bias due to missing results (arising from reporting biases) for each synthesis assessed. | yes |
| Certainty of evidence | 22 | Present assessments of certainty (or confidence) in the body of evidence for each outcome assessed. | yes |
| **DISCUSSION** | | | |
| Discussion | 23a | Provide a general interpretation of the results in the context of other evidence. | yes |
| | 23b | Discuss any limitations of the evidence included in the review. | yes |
| | 23c | Discuss any limitations of the review processes used. | yes |
| | 23d | Discuss implications of the results for practice, policy, and future research. | yes |
| **OTHER INFORMATION** | | | |
| Registration and protocol | 24a | Provide registration information for the review, including register name and registration number, or state that the review was not registered. | yes |
| | 24b | Indicate where the review protocol can be accessed, or state that a protocol was not prepared. | yes |
| | 24c | Describe and explain any amendments to information provided at registration or in the protocol. | yes |
| Support | 25 | Describe sources of financial or non-financial support for the review, and the role of the funders or sponsors in the review. | yes |
| Competing interests | 26 | Declare any competing interests of review authors. | yes |
| Availability of data, code and other materials | 27 | Report which of the following are publicly available and where they can be found: template data collection forms; data extracted from included studies; data used for all analyses; analytic code; any other materials used in the review. | yes |

*From:* Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372:n71. doi: 10.1136/bmj.n71

**Table S2.** list of excluded studies with reasons.

| Excluded Studies | Reason for exclusion |
|---|---|
| El-Galaly TC, Villa D, Gormsen LC, Baech J, Lo A, Cheah CY. FDG-PET/CT in the management of lymphomas: current status and future directions. J Intern Med. 2018 Oct;284(4):358-376. doi: 10.1111/joim.12813. | Review in the field of interest |
| Zwanenburg A, Vallières M, Abdalah MA, Aerts HJWL, Andrearczyk V, Apte A, Ashrafinia S, Bakas S, Beukinga RJ, Boellaard R, Bogowicz M, Boldrini L, Buvat I, Cook GJR, Davatzikos C, Depeursinge A, Desseroit MC, Dinapoli N, Dinh CV, Echegaray S, El Naqa I, Fedorov AY, Gatta R, Gillies RJ, Goh V, Götz M, Guckenberger M, Ha SM, Hatt M, Isensee F, Lambin P, Leger S, Leijenaar RTH, Lenkowicz J, Lippert F, Losnegård A, Maier-Hein KH, Morin O, Müller H, Napel S, Nioche C, Orlhac F, Pati S, Pfaehler EAG, Rahmim A, Rao AUK, Scherer J, Siddique MM, Sijtsema NM, Socarras Fernandez J, Spezi E, Steenbakkers RJHM, Tanadini-Lang S, Thorwarth D, Troost EGC, Upadhaya T, Valentini V, van Dijk LV, van Griethuysen J, van Velden FHP, Whybra P, Richter C, Löck S. The Image Biomarker Standardization Initiative: Standardized Quantitative Radiomics for High-Throughput Image-based Phenotyping. Radiology. 2020 May;295(2):328-338. doi: 10.1148/radiol.2020191145. | Original study not in the field of interest |
| Varasteh Z, Mohanta S, Robu S, Braeuer M, Li Y, Omidvari N, Topping G, Sun T, Nekolla SG, Richter A, Weber C, Habenicht A, Haberkorn UA, Weber WA. Molecular Imaging of Fibroblast Activity After Myocardial Infarction Using a <sup>68</sup>Ga-Labeled Fibroblast Activation Protein Inhibitor, FAPI-04. J Nucl Med. 2019 Dec;60(12):1743-1749. doi: 10.2967/jnumed.119.226993. | Original study not in the field of interest |
| Liu Y. Unusual Illustration of Richter Transformation in Chronic Lymphocytic Leukemia on FDG PET/CT. Clin Nucl Med. 2022 Aug 1;47(8):746-747. doi: 10.1097/RLU.0000000000004125. | Case report in the field of interest |
| Rossi D, Gaidano G. Richter syndrome. Adv Exp Med Biol. 2013;792:173-91. doi:10.1007/978-1-4614-8051-8_8. | Review in the field of interest |
| Barré L, Hovhannisyan N, Bodet-Milin C, Kraeber-Bodéré F, Damaj G. [<sup>18</sup>F]-Fludarabine for Hematological Malignancies. Front Med (Lausanne). 2019 Apr 17;6:77. doi: 10.3389/fmed.2019.00077. | Review not in the field of interest |
| Condoluci A, Rossi D. Treatment of Richter's Syndrome. Curr Treat Options Oncol. 2017 Nov 21;18(12):75. doi: 10.1007/s11864-017-0512-y. | Review not in the field of interest |
| Shaikh F, Janjua A, Van Gestel F, Ahmad A. Richter Transformation of Chronic Lymphocytic Leukemia: A Review of Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography and Molecular Diagnostics. Cureus. 2017 Jan 9;9(1):e968. doi: 10.7759/cureus.968. | Review in the field of interest |
| Khan M, Siddiqi R, Thompson PA. Approach to Richter | Review not in the field of interest |

| | |
|---|---|
| transformation of chronic lymphocytic leukemia in the era of novel therapies. Ann Hematol. 2018 Jan;97(1):1-15. doi: 10.1007/s00277-017-3149-9 | |
| Zhao Z, Hu Y, Li J, Zhou Y, Zhang B, Deng S. Applications of PET in Diagnosis and Prognosis of Leukemia. Technol Cancer Res Treat. 2020 Jan-Dec;19:1533033820956993. doi: 10.1177/1533033820956993. | Review in the field of interest |
| Rossi D, Gaidano G. Richter syndrome: pathogenesis and management. Semin Oncol. 2016 Apr;43(2):311-9. doi: 10.1053/j.seminoncol.2016.02.012. | Review in the field of interest |
| Chen W, Jeudy J. Assessment of Myocarditis: Cardiac MR, PET/CT, or PET/MR? Curr Cardiol Rep. 2019 Jun 26;21(8):76. doi: 10.1007/s11886-019-1158-0. | Review not in the field of interest |
| Zirakchian Zadeh M. Clinical Application of <sup>18</sup>F-FDG-PET Quantification in Hematological Malignancies: Emphasizing Multiple Myeloma, Lymphoma and Chronic Lymphocytic Leukemia. Clin Lymphoma Myeloma Leuk. 2023 Nov;23(11):800-814. doi: 10.1016/j.clml.2023.07.008. | Review not in the field of interest |
| Rossi D. Richter's syndrome: Novel and promising therapeutic alternatives. Best Pract Res Clin Haematol. 2016 Mar;29(1):30-39. doi:10.1016/j.beha.2016.08.006. | Review not in the field of interest |
| Sood A, Parihar AS, Lad D, Kumar R, Singh H, Mittal BR. An Unusual Presentation of Richter's Transformation of Chronic Lymphocytic Leukemia in Liver and Lung on <sup>18</sup>F-Labeled Fluoro-2-Deoxyglucose Positron Emission Tomography/Computed Tomography. Indian J Nucl Med. 2020 Jan-Mar;35(1):70-71. doi: 10.4103/ijnm.IJNM_175_19. | Case report in the field of interest |
| Albano D, Dondi F, Bertagna F, Treglia G. The Role of [<sup>68</sup>Ga]Ga-Pentixafor PET/CT or PET/MRI in Lymphoma: A Systematic Review. Cancers (Basel). 2022 Aug 5;14(15):3814. doi: 10.3390/cancers14153814. | Review not in the field of interest |
| Molica S. FDG/PET in CLL today. Blood. 2014 May 1;123(18):2749-50. doi: 10.1182/blood-2014-03-563700. | Editorial in the field of interest |
| Federmann B, Mueller MR, Steinhilber J, Horger MS, Fend F. Diagnosis of Richter transformation in chronic lymphocytic leukemia: histology tips the scales. Ann Hematol. 2018 Oct;97(10):1859-1868. doi: 10.1007/s00277-018-3390-x. | Original article not in the field of interest |
| Sanz G, Rioja J, Zudaire JJ, Berián JM, Richter JA. PET and prostate cancer. World J Urol. 2004 Nov;22(5):351-2. doi: 10.1007/s00345-004-0418-8. | Review not in the field of interest |
| Hirshoren N, Olayos E, Herschtal A, Ravi Kumar AS, Gyorki DE. Preoperative Positron Emission Tomography for Node-Positive Head and Neck Cutaneous Squamous Cell Carcinoma. Otolaryngol Head Neck Surg. 2018 Jan;158(1):122-126. doi: 10.1177/0194599817731735. | Original article not in the field of interest |
| Yuen R, Wagner M, Richter S, Dufour J, Wuest M, West FG, | Original article not in the field of interest |

| | |
|---|---|
| Wuest F. Design, synthesis, and evaluation of positron emission tomography/fluorescence dual imaging probes for targeting facilitated glucose transporter 1 (GLUT1). Org Biomol Chem. 2021 Apr 14;19(14):3241-3254. doi: 10.1039/d1ob00199j. | |
| Dixon JG, Dimier N, Nielsen T, Zheng J, Marcus R, Morschhauser F, Evens AM, Federico M, Blum KA, Shi Q. End of induction positron emission tomography complete response (PET-CR) as a surrogate for progression-free survival in previously untreated follicular lymphoma. Br J Haematol. 2022 Jul;198(2):333-337. doi: 10.1111/bjh.18217. | Original article not in the field of interest |
| Gupta N, Mittal A, Duggal R, Dadu T, Agarwal A, Handoo A. Hodgkin Variant of Richter's Transformation in Chronic Lymphocytic Leukemia (CLL): An Illustrative Case Report and Literature Review. Int J Hematol Oncol Stem Cell Res. 2021 Oct 1;15(4):249-254. doi: 10.18502/ijhoscr.v15i4.7480. | Original article not in the field of interest |
| Johansson P, Alig S, Richter J, Hanoun C, Rekowski J, Dürig J, Ylstra B, de Jong D, Klapper W, Alizadeh AA, Dührsen U, Hüttmann A. Outcome prediction by interim positron emission tomography and IgM monoclonal gammopathy in diffuse large B-cell lymphoma. Ann Hematol. 2023 Dec;102(12):3445-3455. doi: 10.1007/s00277-023-05393-1. | Original article not in the field of interest |
| Fjordside L, Mens H, Asmar A. Using 18F-FDG PET/CT to rule out Richter transformation as cause of deterioration in a patient with chronic lymphatic leukemia and severe COVID-19: A case report. Medicine (Baltimore). 2021 Nov 5;100(44):e27545. doi: 10.1097/MD.0000000000027545. | Case report in the field of interest |
| Basu S, Alavi A. PET-Based Personalized Management in Clinical Oncology: An Unavoidable Path for the Foreseeable Future. PET Clin. 2016 Jul;11(3):203-7. doi: 10.1016/j.cpet.2016.03.002. | Review not in the field of interest |
| Alessandrino F, DiPiro PJ, Jagannathan JP, Babina G, Krajewski KM, Ramaiya NH, Giardino AA. Multimodality imaging of indolent B cell lymphoma from diagnosis to transformation: what every radiologist should know. Insights Imaging. 2019 Feb 22;10(1):25. doi: 10.1186/s13244-019-0705-y. | Review not in the field of interest |
| London J, Grados A, Fermé C, Charmillon A, Maurier F, Deau B, Crickx E, Brice P, Chapelon-Abric C, Haioun C, Burroni B, Alifano M, Le Jeunne C, Guillevin L, Costedoat-Chalumeau N, Schleinitz N, Mouthon L, Terrier B. Sarcoidosis occurring after lymphoma: report of 14 patients and review of the literature. Medicine (Baltimore). 2014 Nov;93(21):e121. doi: 10.1097/MD.0000000000000121. | Case report not in the field of interest |
| Swords R, Bruzzi J, Giles F. Recent advances in the diagnosis and therapy of Richter's syndrome. Med Oncol. 2007;24(1):17-32. doi: 10.1007/BF02685899. | Review not in the field of interest |
| Chantepie S, Hovhannisyan N, Guillouet S, Pelage JP, Ibazizene M, Bodet-Milin C, Carlier T, Gac AC, Réboursière E, Vilque JP, | Original article not in the field of interest |

| | |
|---|---|
| Kraeber-Bodéré F, Manrique A, Damaj G, Leporrier M, Barré L. <sup>18</sup>F-Fludarabine PET for Lymphoma Imaging: First-in-Humans Study on DLBCL and CLL Patients. J Nucl Med. 2018 Sep;59(9):1380-1385. doi: 10.2967/jnumed.117.206920. | |
| Broecker-Preuss M, Becher-Boveleth N, Müller SP, Hüttmann A, Hanoun C, Grafe H, Richter J, Klapper W, Rekowski J, Bockisch A, Dührsen U. Impact of germline polymorphisms in genes regulating glucose uptake on positron emission tomography findings and outcome in diffuse large B-cell lymphoma: results from the PETAL trial. J Cancer Res Clin Oncol. 2022 Oct;148(10):2611-2621. doi:10.1007/s00432-021-03796-z. | Original article not in the field of interest |
| Giannoni P, Marini C, Cutrona G, Todoerti K, Neri A, Ibatici A, Sambuceti G, Pigozzi S, Mora M, Ferrarini M, Fais F, de Totero D. A High Percentage of CD16+ Monocytes Correlates with the Extent of Bone Erosion in Chronic Lymphocytic Leukemia Patients: The Impact of Leukemic B Cells in Monocyte Differentiation and Osteoclast Maturation. Cancers (Basel). 2022 Dec 3;14(23):5979. doi:10.3390/cancers14235979. | Original article not in the field of interest |
| Ayubcha C, Hosoya H, Seraj SM, Zadeh MZ, Werner T, Alavi A. The role of <sup>18</sup>F-FDG PET in the assessment of a benign hematological disorder: polycythemia. Hell J Nucl Med. 2019 Jan-Apr;22(1):4-5. doi:10.1967/s002449910951 | Editorial not in the field of interest |
| Albano D, Ferro P, Bosio G, Fallanca F, Re A, Tucci A, Maria Ferreri AJ, Angelillo P, Gianolli L, Giubbini R, Bertagna F. Diagnostic and Clinical Impact of Staging <sup>18</sup>F-FDG PET/CT in Mantle-Cell Lymphoma: A Two-Center Experience. Clin Lymphoma Myeloma Leuk. 2019 Aug;19(8):e457-e464. doi: 10.1016/j.clml.2019.04.016. | Original article not in the field of interest |
| MacManus MP, Hofman MS, Hicks RJ, Campbell BA, Wirth A, Seymour JF, Haynes N, Burbury K. Abscopal Regressions of Lymphoma After Involved-Site Radiation Therapy Confirmed by Positron Emission Tomography. Int J Radiat Oncol Biol Phys. 2020 Sep 1;108(1):204-211. doi: 10.1016/j.ijrobp.2020.02.636. | Original article not in the field of interest |
| Prexler C, Knape MS, Erlewein-Schweizer J, Roll W, Specht K, Woertler K, Weichert W, von Luettichau I, Rossig C, Hauer J, Richter GHS, Weber W, Burdach S. Correlation of Transcriptomics and FDG-PET SUVmax Indicates Reciprocal Expression of Stemness-Related Transcription Factor and Neuropeptide Signaling Pathways in Glucose Metabolism of Ewing Sarcoma. Cancers (Basel). 2022 Dec 5;14(23):5999. doi: 10.3390/cancers14235999. | Original article not in the field of interest |
| Sanz G, Robles JE, Giménez M, Arocena J, Sánchez D, Rodriguez-Rubio F, Rosell D, Richter JA, Berián JM. Positron emission tomography with 18fluorine-labelled deoxyglucose: utility in localized and advanced prostate cancer. BJU Int. 1999 Dec;84(9):1028-31. doi: 10.1046/j.1464-410x.1999.00349.x. | Original article not in the field of interest |
| Gajendra S, Sharma R, Sahoo MK. Triple cancer: chronic | Case report not in the field of interest |

| | |
|---|---|
| lymphocytic leukemia with bladder and prostate carcinoma. Malays J Pathol. 2015 Aug;37(2):159-63. | |
| Yılmaz S, Ozhan M, Asa S, Sağer MS, Biricik FS, Halaç M, Sönmezoğlu K. Detection of Hodgkin Transformation in a Case of Chronic Lymphocytic Leukemia by PET/CT. Mol Imaging Radionucl Ther. 2014 Jun;23(2):67-9. doi: 10.4274/mirt.362. | Case report in the field of interest |
| Rezvani S, Tominna M, Al-Katib S, Smith MD, Cousineau C, Al-Katib A. Lymphomatoid Granulomatosis in a Patient with Chronic Lymphocytic Leukemia and Rapidly Progressing Peribronchovascular Pulmonary Infiltrates. Case Rep Pulmonol. 2019 Jan 21;2019:9870494. doi: 10.1155/2019/9870494 | Case report in the field of interest |
| Martí-Climent JM, Prieto E, Morán V, Sancho L, Rodríguez-Fraile M, Arbizu J, García-Velloso MJ, Richter JA. Effective dose estimation for oncological and neurological PET/CT procedures. EJNMMI Res. 2017 Dec;7(1):37. doi: 10.1186/s13550-017-0272-5 | Original article not in the field of interest |
| Lavalle M, Minordi LM, Hohaus S, Manfredi R, Rufini V. Richter Syndrome Presenting With Colon Localization. Clin Nucl Med. 2019 Feb;44(2):e87-e89. doi: 10.1097/RLU.0000000000002393. | Case report in the field of interest |
| Fiz F, Marini C, Piva R, Miglino M, Massollo M, Bongioanni F, Morbelli S, Bottoni G, Campi C, Bacigalupo A, Bruzzi P, Frassoni F, Piana M, Sambuceti G. Adult advanced chronic lymphocytic leukemia: computational analysis of whole- body CT documents a bone structure alteration. Radiology. 2014 Jun;271(3):805-13. doi: 10.1148/radiol.14131944. | Original article not in the field of interest |
| Bastarrika G, García-Velloso MJ, Lozano MD, Montes U, Torre W, Spiteri N, Campo A, Seijo L, Alcaide AB, Pueyo J, Cano D, Vivas I, Cosín O, Domínguez P, Serra P, Richter JA, Montuenga L, Zulueta JJ. Early lung cancer detection using spiral computed tomography and positron emission tomography. Am J Respir Crit Care Med. 2005 Jun 15;171(12):1378-83. doi: 10.1164/rccm.200411-1479OC | Original article not in the field of interest |
| Richter N, Nellessen N, Dronse J, Dillen K, Jacobs HIL, Langen KJ, Dietlein M, Kracht L, Neumaier B, Fink GR, Kukolja J, Onur OA. Spatial distributions of cholinergic impairment and neuronal hypometabolism differ in MCI due to AD. Neuroimage Clin. 2019;24:101978. doi: 10.1016/j.nicl.2019.101978. | Original article not in the field of interest |
| Hodgson YA, Jones SG, Knight H, Sovani V, Fox CP. Herpes Simplex Necrotic Lymphadenitis Masquerading as Richter's Transformation in Treatment-Naïve Patients With Chronic Lymphocytic Leukemia. J Hematol. 2019 Jun;8(2):79-82. doi: 10.14740/jh517. | Original article not in the field of interest |
| Casquero-Veiga M, Romero-Miguel D, MacDowell KS, Torres-Sanchez S, Garcia-Partida JA, Lamanna-Rama N, Gómez-Rangel V, Romero-Miranda A, Berrocoso E, Leza JC, Arango C, Desco M, Soto-Montenegro ML. Omega-3 fatty acids during adolescence prevent schizophrenia-related behavioural deficits: | Original article not in the field of interest |

| | |
|---|---|
| Neurophysiological evidences from the prenatal viral infection with Polyl:C. Eur Neuropsychopharmacol. 2021 May;46:14-27. doi: 10.1016/j.euroneuro.2021.02.001. | |
| Richter JA, Rodríguez M, Rioja J, Peñuelas I, Martí-Climent J, Garrastachu P, Quincoces G, Zudaire J, García-Velloso MJ. Dual tracer 11C-choline and FDG-PET in the diagnosis of biochemical prostate cancer relapse after radical treatment. Mol Imaging Biol. 2010 Apr;12(2):210-7. doi: 10.1007/s11307-009-0243-y. | Original article not in the field of interest |
| Prieto E, García-Velloso MJ, Rodríguez-Fraile M, Morán V, García-García B, Guillén F, Morales MI, Sancho L, Peñuelas I, Richter JÁ, Martí-Climent JM. Significant dose reduction is feasible in FDG PET/CT protocols without compromising diagnostic quality. Phys Med. 2018 Feb;46:134-139. doi: 10.1016/j.ejmp.2018.01.021. | Original article not in the field of interest |
| Alfonso A, Redondo M, Rubio T, Del Olmo B, Rodríguez-Wilhelmi P, García-Velloso MJ, Richter JA, Páramo JA, Lecumberri R. Screening for occult malignancy with FDG-PET/CT in patients with unprovoked venous thromboembolism. Int J Cancer. 2013 Nov;133(9):2157-64. doi: 10.1002/ijc.28229. | Original article not in the field of interest |
| Ulaner GA, Sawan P. Transient Osteoporosis of the Hip on FDG PET/CT. Clin Nucl Med. 2017 May;42(5):401-402. doi: 10.1097/RLU.0000000000001630. | Case report not in the field of interest |
| Pudis M, Gràcia-Sánchez L, Muñoz-Palomar A, Sánchez-Rodríguez IE, Cortés-Romera M. Richter's transformation with isolated cardiac involvement diagnosed by 2-[<sup>18</sup>F]FDG PET/CT scan. J Nucl Cardiol. 2023 Feb;30(1):427-430. doi: 10.1007/s12350-021-02845-x. | Case report in the field of interest |
| García Vicente AM, Jiménez Londoño GA, Hernández Ruiz B, Soriano Castrejón Á. Richter's syndrome: Utility of $^{18}$F-FDG PET/CT. Rev Esp Med Nucl Imagen Mol. 2013 Mar;32(2):102-4. doi: 10.1016/j.remn.2012.08.001. | Case report in the field of interest |
| Marini C, Bruno S, Fiz F, Campi C, Piva R, Cutrona G, Matis S, Nieri A, Miglino M, Ibatici A, Maria Orengo A, Maria Massone A, Neumaier CE, Totero D, Giannoni P, Bauckneht M, Pennone M, Tenca C, Gugiatti E, Bellini A, Borra A, Tedone E, Efetürk H, Rosa F, Emionite L, Cilli M, Bagnara D, Brucato V, Bruzzi P, Piana M, Fais F, Sambuceti G. Functional Activation of Osteoclast Commitment in Chronic Lymphocytic Leukaemia: a Possible Role for RANK/RANKL Pathway. Sci Rep. 2017 Oct 26;7(1):14159. doi: 10.1038/s41598-017-12761-1. | Original article not in the field of interest |
| Okada J, Yoshikawa K, Imazeki K, Minoshima S, Uno K, Itami J, Kuyama J, Maruno H, Arimizu N. The use of FDG-PET in the detection and management of malignant lymphoma: correlation of uptake with prognosis. J Nucl Med. 1991 Apr;32(4):686-91. | Original article not in the field of interest |
| Zschaeck S, Löck S, Leger S, Haase R, Bandurska-Luque A, Appold S, Kotzerke J, Zips D, Richter C, Gudziol V, Schreiber A, | Original article not in the field of interest |

| | |
|---|---|
| Zöphel K, Baumann M, Krause M. FDG uptake in normal tissues assessed by PET during treatment has prognostic value for treatment results in head and neck squamous cell carcinomas undergoing radiochemotherapy. Radiother Oncol. 2017 Mar;122(3):437-444. doi: 10.1016/j.radonc.2017.01.019. | |
| Yamane T, Park MJ, Richter D, Nekolla SG, Javadi MS, Lapa C, Samnick S, Buck AK, Herrmann K, Higuchi T. Small-animal PET imaging of isolated perfused rat heart. J Nucl Med. 2014 Mar;55(3):495-9. doi: 10.2967/jnumed.113.129429. | Original article not in the field of interest |
| Merdin A, Yıldız J, Dal Mehmet S, Çakar MK, Batgi H, Tekgündüz E, Onursever A, Altuntaş F. A 80-Year-Old Woman with B-Cell Prolymphocytic Leukemia. Hematol Rep. 2017 Mar 22;9(1):6995. doi: 10.4081/hr.2017.6995. | Case report not in the field of interest |
| Arbizu J, Prieto E, Martínez-Lage P, Martí-Climent JM, García-Granero M, Lamet I, Pastor P, Riverol M, Gómez-Isla MT, Peñuelas I, Richter JA, Weiner MW; Alzheimer's Disease Neuroimaging Initiative. Automated analysis of FDG PET as a tool for single-subject probabilistic prediction and detection of Alzheimer's disease dementia. Eur J Nucl Med Mol Imaging. 2013 Sep;40(9):1394-405. doi:10.1007/s00259-013-2458-z. | Original article not in the field of interest |
| Kader I, Leavers B, Shashinder S, Wylie B, Chi KK, Sundaresan P. Synchronous or metachronous lymphoma and metastatic cutaneous squamous cell carcinoma in the head and neck region: a diagnostic and management dilemma. J Laryngol Otol. 2016 Jul;130 Suppl 4:S45-9. doi: 10.1017/S002221511600832X. | Original article not in the field of interest |
| Panizo C, Pérez-Salazar M, Bendandi M, Rodríguez-Calvillo M, Boán JF, García-Velloso MJ, Richter J, Rocha E. Positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual Hodgkin's disease mediastinal masses. Leuk Lymphoma. 2004 Sep;45(9):1829-33. doi: 10.1080/1042819042000223813. | Original article not in the field of interest |
| Prieto E, Martí-Climent JM, Morán V, Sancho L, Barbés B, Arbizu J, Richter JA. Brain PET imaging optimization with time of flight and point spread function modelling. Phys Med. 2015 Dec;31(8):948-955. doi: 10.1016/j.ejmp.2015.07.001. | Original article not in the field of interest |
| Tiling R, Linke R, Untch M, Richter A, Fieber S, Brinkbäumer K, Tatsch K, Hahn K. 18F-FDG PET and 99mTc-sestamibi scintimammography for monitoring breast cancer response to neoadjuvant chemotherapy: a comparative study. Eur J Nucl Med. 2001 Jun;28(6):711-20. doi: 10.1007/s002590100539. | Original article not in the field of interest |
| Krarup MMK, Nygård L, Vogelius IR, Andersen FL, Cook G, Goh V, Fischer BM. Heterogeneity in tumours: Validating the use of radiomic features on <sup>18</sup>F-FDG PET/CT scans of lung cancer patients as a prognostic tool. Radiother Oncol. 2020 Mar;144:72-78. doi: 10.1016/j.radonc.2019.10.012. | Original article not in the field of interest |
| Abdulqadhr G, Molin D, Aström G, Suurküla M, Johansson L, | Original article not in the field of interest |

| | |
|---|---|
| Hagberg H, Ahlström H. Whole-body diffusion-weighted imaging compared with FDG-PET/CT in staging of lymphoma patients. Acta Radiol. 2011 Mar 1;52(2):173-80. doi: 10.1258/ar.2010.100246. | |
| Bandurska-Luque A, Löck S, Haase R, Richter C, Zöphel K, Perrin R, Appold S, Krause M, Steinbach J, Kotzerke J, Hofheinz F, Zips D, Baumann M, Troost EGC. Correlation between FMISO-PET based hypoxia in the primary tumour and in lymph node metastases in locally advanced HNSCC patients. Clin Transl Radiat Oncol. 2019 Feb 15;15:108-112. doi: 10.1016/j.ctro.2019.02.002. | Original article not in the field of interest |
| Jacobs SA, Harrison AM, Swerdlow SH, Foon KA, Avril N, Vidnovic N, Joyce J, DeMonaco N, McCarty KS Jr. Radioisotopic localization of (90)Yttrium-ibritumomab tiuxetan in patients with CD20+ non-Hodgkin's lymphoma. Mol Imaging Biol. 2009 Jan-Feb;11(1):39-45. doi: 10.1007/s11307-008-0170-3. | Original article not in the field of interest |
| García-Velloso MJ, López G, Galán MJ, Meiriño R, Martí JM, Boán J, Richter JA. Valor clínico de la tomografía de emisión de positrones con F-18-FDG en el seguimiento de pacientes con cáncer de ovario [Clinical value of positron emission tomography with F-18-FDG in the follow up of patients with cancer of the ovary]. An Sist Sanit Navar. 2002 Jan-Apr;25(1):21-9. Spanish. doi: 10.23938/ASSN.0788. | Original article not in the field of interest |
| Ozturk K, Ustun C, Khaja S, Li F, Rischall M, Cayci Z. Concomitant cutaneous squamous cell carcinoma and chronic lymphocytic leukemia in a patient: The utility of <sup>18</sup> F-FDG PET/CT in differentiation of nodal metastasis. Am J Hematol. 2018 Aug;93(4):597-598. doi: 10.1002/ajh.25041. | Case report not in the field of interest |
| Israel I, Richter D, Stritzker J, van Ooschot M, Donat U, Buck AK, Samnick S. PET imaging with [$^{68}$Ga]NOTA-RGD for prostate cancer: a comparative study with [$^{18}$F]fluorodeoxyglucose and [$^{18}$F]fluoroethylcholine. Curr Cancer Drug Targets. 2014;14(4):371-9. doi: 10.2174/1568009614666140403123452. | Original article not in the field of interest |
| Eichler M, Richter S, Hohenberger P, Kasper B, Andreou D, Heidt V, Bornhäuser M, Schmitt J, Schuler MK. Current State of Sarcoma Care in Germany: Results of an Online Survey of Physicians. Oncol Res Treat. 2019;42(11):589-598. doi: 10.1159/000502758. | Original article not in the field of interest |
| Richter S, Wuest M, Bergman CN, Way JD, Krieger S, Rogers BE, Wuest F. Rerouting the metabolic pathway of (18)F-labeled peptides: the influence of prosthetic groups. Bioconjug Chem. 2015 Feb 18;26(2):201-12. doi: 10.1021/bc500599m. | Original article not in the field of interest |
| Tsai SY, Shiau YC, Wang SY, Wu YW. Conjunctival Melanoma on 18F-FDG PET/CT as a Second Primary Cancer. Clin Nucl Med. 2016 Mar;41(3):237-8. doi: 10.1097/RLU.0000000000001082. | Case report not in the field of interest |
| Calvo R, Martí-Climent JM, Richter JA, Peñuelas I, Crespo-Jara A, Villar LM, García-Velloso MJ. Three-dimensional clinical PET in | Original article not in the field of interest |

| | |
|---|---|
| lung cancer: validation and practical strategies. J Nucl Med. 2000 Mar;41(3):439-48. | |
| Salem U, Zhang L, Jorgensen JL, Kumar R, Amini B. Adhesive capsulitis mimicking metastasis on 18F-FDG-PET/CT. Clin Nucl Med. 2015 Feb;40(2):e145-7. doi: 10.1097/RLU.0000000000000524 | Case report not in the field of interest |
| Garcia-Velloso MJ, Bastarrika G, de-Torres JP, Lozano MD, Sanchez-Salcedo P, Sancho L, Nuñez-Cordoba JM, Campo A, Alcaide AB, Torre W, Richter JA, Zulueta JJ. Assessment of indeterminate pulmonary nodules detected in lung cancer screening: Diagnostic accuracy of FDG PET/CT. Lung Cancer. 2016 Jul;97:81-6. doi: 10.1016/j.lungcan.2016.04.025. | Original article not in the field of interest |
| Douglas AP, Atarod M, Prince HM. FDG-PET/CT findings, the vital clue to rare diagnosis of herpes simplex virus lymphadenitis simulating Richter transformation. Pathology. 2019 Jan;51(1):102-104. doi: 10.1016/j.pathol.2018.08.016. | Case report in the field of interest |
| Glazebrook KN, Zingula S, Jones KN, Fazzio RT. Breast imaging findings in haematological malignancies. Insights Imaging. 2014 Dec;5(6):715-22. doi: 10.1007/s13244-014-0344-2. | Original article not in the field of interest |
| Roolf C, Richter A, Konkolefski C, Knuebel G, Sekora A, Krohn S, Stenzel J, Krause BJ, Vollmar B, Murua Escobar H, Junghanss C. Decitabine demonstrates antileukemic activity in B cell precursor acute lymphoblastic leukemia with MLL rearrangements. J Hematol Oncol. 2018 May 4;11(1):62. doi: 10.1186/s13045-018-0607-3. | Original article not in the field of interest |
| Chen Q, Zhang J, Huang H, Qiu T, Jin Z, Shi Y, Zhu H, Fan L, Li J, Shi W, Miao Y. Histiocytic necrotizing lymphadenitis with hemophagocytic lymphohistiocytosis in adults: A single-center analysis of 5 cases. Immun Inflamm Dis. 2024 Feb;12(2):e1202. doi: 10.1002/iid3.1202. | Case series not in the field of interest |
| Reddy CG, Mauermann ML, Solomon BM, Ringler MD, Jerath NU, Begna KH, Amrami KK, Spinner RJ. Neuroleukemiosis: an unusual cause of peripheral neuropathy. Leuk Lymphoma. 2012 Dec;53(12):2405-11. doi: 10.3109/10428194.2012.691480. | Case report not in the field of interest |
| Bleeker-Rovers CP, Vos FJ, de Kleijn EMHA, Mudde AH, Dofferhoff TSM, Richter C, Smilde TJ, Krabbe PFM, Oyen WJG, van der Meer JWM. A prospective multicenter study on fever of unknown origin: the yield of a structured diagnostic protocol. Medicine (Baltimore). 2007 Jan;86(1):26-38. doi: 10.1097/MD.0b013e31802fe858. | Original article not in the field of interest |
| Richter JA, García-Velloso MJ, Domínguez I, Quincoces G, Prieto E, Rodríguez Fraile M. Tomografía por emisión de positrones en el cáncer de mama [Positron-emission tomography in breast cancer]. Rev Med Univ Navarra. 2008 Jan-Mar;52(1):4-12. | Review not in the field of interest |
| Richter JP, Goroncy AK, Ronimus RS, Sutherland-Smith AJ. The Structural and Functional Characterization of Mammalian ADP-dependent Glucokinase. J Biol Chem. 2016 Feb 19;291(8):3694-704. doi: 10.1074/jbc.M115.679902. | Original article not in the field of interest |

| | |
|---|---|
| Prieto E, Domínguez-Prado I, García-Velloso MJ, Peñuelas I, Richter JÁ, Martí-Climent JM. Impact of time-of-flight and point-spread-function in SUV quantification for oncological PET. Clin Nucl Med. 2013 Feb;38(2):103-9. doi: 10.1097/RLU.0b013e318279b9df. | Original article not in the field of interest |
| Kritikos N, Priftakis D, Stavrinides S, Kleanthous S, Sarafianou E. Nuclear medicine techniques in Merkel cell carcinoma: A case report and review of the literature. Oncol Lett. 2015 Sep;10(3):1610-1616. doi: 10.3892/ol.2015.3377. | Case report not in the field of interest |
| García Velloso MJ, Quesada J, Martí JM, Azinovic I, Peñuelas I, Alcalde J, Richter JA. Tomografía de emisión de positrones con F-18-FDG: una nueva técnica en la evaluación de pacientes con neoplasias de cabeza y cuello [Positron emission tomography with F-18-FDG: a new tool in the evaluation of patients with head and neck tumors]. An Sist Sanit Navar. 1999 May-Aug;22(2):155-65. | Original article not in the field of interest |
| Iğdem S, Okkan S, Unalan B, Iğdem A, Ferhanoğlu B. Cervical cancer coexisting with small lymphocytic lymphoma detected during positron emission tomography/computed tomography simulation: a case report. Eur J Gynaecol Oncol. 2008;29(4):405-7. | Case report not in the field of interest |
| Prieto E, Martí-Climent JM, Gómez-Fernández M, García-Velloso MJ, Valero M, Garrastachu P, Aristu J, Alcázar JL, Torre W, Hernández JL, Pardo FJ, Peñuelas I, Richter JA. Validación de técnicas de segmentación para la tomografía por emisión de positrones mediante imágenes ex-vivo de piezas quirúrgicas oncológicas [Validation of segmentation techniques for positron emission tomography using ex-vivo images of oncological surgical specimens]. Rev Esp Med Nucl Imagen Mol. 2014 Mar-Apr;33(2):79-86. Spanish. doi: 10.1016/j.remn.2013.06.010. | Original article not in the field of interest |
| Li Y, Wei J, Mao X, Gao Q, Liu L, Cheng P, Liu L, Zhang X, Zhang K, Wang J, Zhu L, Zhou J, Zhang Y, Meng L, Sun H, Li D, Huang M, Huang W, Deng J, Zhang D. Flow Cytometric Immunophenotyping Is Sensitive for the Early Diagnosis of De Novo Aggressive Natural Killer Cell Leukemia (ANKL): A Multicenter Retrospective Analysis. PLoS One. 2016 Aug 2;11(8):e0158827. doi: 10.1371/journal.pone.0158827. | Original article not in the field of interest |
| Osman MM, Altinyay ME, Abdelmalik AG, Brickman TM, Varvares MA, Nguyen NC. FDG PET/CT incidental diagnosis of a synchronous bladder cancer as a fourth malignancy in a patient with head and neck cancer. Clin Nucl Med. 2011 Jun;36(6):496-7. doi: 10.1097/RLU.0b013e318217393f. | Case report not in the field of interest |
| Thom AR, Hamerschlak N, Teles VG, Osawa A, Santos FP, Pasqualin Dda C, Wagner J, Yamaga LY, Cunha ML, Campos Neto Gde C, Funari MB. Normalization of lymphocyte count after high ablative dose of I-131 in a patient with chronic lymphoid leukemia and secondary papillary carcinoma of the | Case report not in the field of interest |

| | |
|---|---|
| thyroid. Case report. Einstein (Sao Paulo). 2014 Jan-Mar;12(1):100-5. doi: 10.1590/s1679-45082014rc2657. | |
| Dillen KNH, Jacobs HIL, Kukolja J, Richter N, von Reutern B, Onur ÖA, Langen KJ, Fink GR. Functional Disintegration of the Default Mode Network in Prodromal Alzheimer's Disease. J Alzheimers Dis. 2017;59(1):169-187. doi: 10.3233/JAD-161120. | Original article not in the field of interest |
| Richter JA, García-Velloso MJ, Pérez-Equiza C, Gámez C, Pérez-Calvo J, Gorosquieta A, Crespo A. PET-FDG Versus CT in the Staging and Detection of Relapse in Patients with Hodgkin's Disease or Non-Hodgkin Lymphoma. Two Years Experience. Clin Positron Imaging. 1998 Sep;1(4):248. doi: 10.1016/s1095-0397(98)00038-7. | Original article not in the field of interest |
| Rasmussen JH, Håkansson K, Rasmussen GB, Vogelius IR, Friborg J, Fischer BM, Bentzen SM, Specht L. A clinical prognostic model compared to the newly adopted UICC staging in an independent validation cohort of P16 negative/positive head and neck cancer patients. Oral Oncol. 2018 Jun;81:52-60. doi: 10.1016/j.oraloncology.2018.04.009. | Original article not in the field of interest |
| Kiyosawa M, Bosley TM, Alavi A, Gupta N, Rhodes CH, Chawluk J, Kushner M, Savino PJ, Sergott RC, Schatz NJ, et al. Positron emission tomography in a patient with progressive multifocal leukoencephalopathy. Neurology. 1988 Dec;38(12):1864-7. doi: 10.1212/wnl.38.12.1864. | Case report not in the field of interest |
| Richter JA, Torre W, Gámez C, Aramendia JM, Crespo A, Nicolás A, Brugarolas A. Valor de la tomografía por emisión de positrones (PET)-18FDG en el cáncer de pulmón [Value of Pet-18FDG in lung cancer]. Med Clin (Barc). 1999 Nov 6;113(15):567-71. | Original article not in the field of interest |
| Maffione AM, Rampin L, Paolini R, Rodella E, Lisato LC, Ballotta MR, Pavanato G, Montesi G, Colletti PM, Rubello D. Epstein-Barr Virus-Positive Mucocutaneous Ulcer Mimicking Rectal Carcinoma at 18F-FDG PET/CT. Clin Nucl Med. 2017 Aug;42(8):645-646. doi: 10.1097/RLU.0000000000001725. | Case report not in the field of interest |
| García-Velloso MJ, Jurado M, Ceamanos C, Aramendía JM, Garrastachu MP, López-García G, Richter JA. Diagnostic accuracy of FDG PET in the follow-up of platinum-sensitive epithelial ovarian carcinoma. Eur J Nucl Med Mol Imaging. 2007 Sep;34(9):1396-405. doi: 10.1007/s00259-007-0366-9. | Original article not in the field of interest |

| | |
|---|---|
| Dyer MJ, Majid A, Walewska R, Gesk S, Harder L, Siebert R, Morgan B. Splenic infarction associated with rapidly progressive chronic lymphocytic leukemia with complex karyotype and ATM mutation. Leuk Res. 2011 May;35(5):e55-7. doi: 10.1016/j.leukres.2010.10.033. | Case report not in the field of interest |
| Zheng XQ, Ding CY, Zou YX, Zhu HY, Wang L, Fan L, Xu W, Li JY. [Roles of PET/CT in Predicting the Prognosis of Diffuse Large B Cell Lymphoma Patients Treated with Chimeric Antigen Receptor T Cell Therapy]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2020 Aug;28(4):1189-1196. Chinese. doi: 10.19746/j.cnki.issn.1009-2137.2020.04.018. | Original article not in the field of interest |
| Kaminek M, Meluzin J, Panovský R, Metelkova I, Budikova M, Richter M. Long-term results of intracoronary bone marrow cell transplantation: the potential of gated sestamibi SPECT/FDG PET imaging to select patients with maximum benefit from cell therapy. Clin Nucl Med. 2010 Oct;35(10):780-7. doi: 10.1097/RLU.0b013e3181e4d9c5. | Original article not in the field of interest |
| Agelopoulos K, Richter GH, Schmidt E, Dirksen U, von Heyking K, Moser B, Klein HU, Kontny U, Dugas M, Poos K, Korsching E, Buch T, Weckesser M, Schulze I, Besoke R, Witten A, Stoll M, Köhler G, Hartmann W, Wardelmann E, Rossig C, Baumhoer D, Jürgens H, Burdach S, Berdel WE, Müller-Tidow C. Deep Sequencing in Conjunction with Expression and Functional Analyses Reveals Activation of FGFR1 in Ewing Sarcoma. Clin Cancer Res. 2015 Nov 1;21(21):4935-46. doi: 10.1158/1078-0432.CCR-14-2744. | Original article not in the field of interest |
| Rioja Zuazu J, Rodríguez M, Rincón Mayans A, Sansi AS, Zudaire Bergera JJ, Martínez-Monge R, Richter JA, Berián Polo JM. Valor de la PET en la recurrencia del cáncer de próstata con PSA < 5 ng/ml [Usefulness of PET scans in diagnosing recurrent prostate cancer. Prostate with PSA level < 5 ng/ml]. Actas Urol Esp. 2009 Sep;33(8):844-52. Spanish. doi: 10.1016/s0210-4806(09)72870-0. | Original article not in the field of interest |
| Martí-Climent J, Peñuelas I, Calvo R, Giménez M, Gámez C, Richter J. Utilización de un ciclotrón para la producción de radionucleidos emisores de positrones [Use of a cyclotron in the production of positron emitting radionuclides]. Rev Esp Med Nucl. 1999 Aug;18(4):261-7 | Original article not in the field of interest |

| | |
|---|---|
| Meller B, Sommer K, Gerl J, von Hof K, Surowiec A, Richter E, Wollenberg B, Baehre M. High energy probe for detecting lymph node metastases with 18F-FDG in patients with head and neck cancer. Nuklearmedizin. 2006;45(4):153-9. | Original article not in the field of interest |
| Richter JA, Torre W, García MJ, Aramendia JM, Giménez M, Brugarolas A. PET-FDG in the Preoperative Evaluation of Non Small Cell Lung Cancer (NSCLC) Staging. A Comparison with CT Scanning and MRI. Clin Positron Imaging. 1998 Sep;1(4):247. doi: 10.1016/s1095-0397(98)00037-5. | Original article not in the field of interest |
| Tabata R, Iwama H, Tabata C, Yasumizu R, Kojima M. CD5- and CD23-positive splenic diffuse large B-cell lymphoma with very low CD20 expression. J Clin Exp Hematop. 2014;54(2):155-61. doi: 10.3960/jslrt.54.155. | Original article not in the field of interest |
| Beylergil V, Simmons MZ, Ulaner G, Jurcic J, Hibshoosh H, Carrasquillo JA. FDG PET/CT findings in a rare case of giant fibrovascular polyp of the esophagus harboring atypical lipomatous tumor/well-differentiated liposarcoma. Clin Nucl Med. 2014 Mar;39(3):288-91. doi: 10.1097/RLU.0000000000000358. | Case report not in the field of interest |
| Richter GT, Mennemeier M, Bartel T, Chelette KC, Kimbrell T, Triggs W, Dornhoffer JL. Repetitive transcranial magnetic stimulation for tinnitus: a case study. Laryngoscope. 2006 Oct;116(10):1867-72. doi: 10.1097/01.mlg.0000234936.82619.69. | Case report not in the field of interest |
| Khashab T, Sehgal L, Medeiros LJ, Samaniego F. Spontaneous regression of interdigitating dendritic sarcoma in a patient with concurrent small lymphocytic lymphoma. BMJ Case Rep. 2015 Jun 12;2015:bcr2014209014. doi: 10.1136/bcr-2014-209014. | Case report not in the field of interest |
| Richter WS. Imaging biomarkers as surrogate endpoints for drug development. Eur J Nucl Med Mol Imaging. 2006 Jul;33 Suppl 1:6-10. doi: 10.1007/s00259-006-0129-z. | Editorial not in the field of interest |
| Schuler MK, Richter S, Platzek I, Beuthien-Baumann B, Wieczorek K, Hamann C, Mohm J, Ehninger G. Trabectedin in the neoadjuvant treatment of high-grade pleomorphic sarcoma: report of a rare case and literature review. Case Rep Oncol Med. 2013;2013:320797. doi: 10.1155/2013/320797. | Case report not in the field of interest |
| Mahmood S, Martínez de Llano SR, Sajid S. False positive FDG-PET extensive diffuse abdominal tracer activity in a patient with CLL on whole-body 18FDG-PET/CT indicative of Ritcher's transformation. Nuklearmedizin. 2009;48(6):N69-70. | Case report in the field of interest |

| | |
|---|---|
| Torre W, Garcia-Velloso MJ, Galbis J, Fernandez O, Richter J. FDG-PET detection of primary lung cancer in a patient with an isolated cerebral metastasis. J Cardiovasc Surg (Torino). 2000 Jun;41(3):503-5. | Case report not in the field of interest |
| Gorospe Sarasúa L, Jaureguízar-Oriol A, Almonacid-Sánchez C, Rioja-Martín ME. Richter Syndrome With Extensive Isolated Pleural Extranodal Involvement: The Importance of PET/CT Imaging. Arch Bronconeumol. 2017 Nov;53(11):644-646. English, Spanish. doi: 10.1016/j.arbres.2017.03.006. | Case report in the field of interest |
| Betts AM, Banks KP, Solberg AO. Unsuspected perforated Richter hernia in the inguinal canal detected by F-18 FDG PET/CT. Clin Nucl Med. 2011 Dec;36(12):1118-9. doi: 10.1097/RLU.0b013e3182335ddf. | Case report in the field of interest |
| Gajendra S, Gogia A, Tanwar P, Sahoo MK, Bhethanabhotla S, Durgapal P, Gupta R. Synchronous metastatic pulmonary adenocarcinoma with small cell lymphoma. Leuk Lymphoma. 2014 Jul;55(7):1678-80. doi: 10.3109/10428194.2013.850166. | Case report not in the field of interest |
| Banzo J, Ubieto MA, Giraldo P, Yus C, Santapau A, Parra A. Hallazgo accidental de un adenoma túbulo-velloso de recto mediante (18)F-FDG PET en un paciente diagnosticado de linfoma linfocítico [Accidental finding of a tubulovellous adenoma of rectum by 18F-FDG PET in a male patient diagnosed of lymphocytic lymphoma]. Rev Esp Med Nucl. 2011 Jul-Aug;30(4):256-7. Spanish. doi: 10.1016/j.remn.2010.10.014. | Case report not in the field of interest |
| Bernardi S, De Nardis L, Macci E, Fiorelli M, Francia A. Multi-domain cognitive impairment disclosed before the diagnosis of chronic lymphocytic leukaemia: an autoimmune/paraneoplastic disorder? Neurol Sci. 2013 May;34(5):801-3. doi: 10.1007/s10072-012-1141-7. | Case report not in the field of interest |